5/95 – 10/95 ENTICES – Enoxaparin and Ticlopidine after Elective Stenting (multi-center, randomized trial).

Sponsors: Rhone Poulenc Rorer & Mallinckrodt. 14 patients enrolled.

2/96 – 12/96 PURSUIT – Platelet IIb/IIIa Underpinning the Receptor for Suppression of Unstable Ischemia

Trial (10,948 patient, multi-center, randomized trial). Sponsors: Cor Therapeutics Inc., & Schering Plough Corporation. 18 patients enrolled.

5/96 – 10/96 TECBEST – Transluminal Extraction Catheter Before Stent (500 patient, multi-center,

randomized trial). Sponsor: University of Alabama at Birmingham. 6 patients enrolled.

6/96 – 1/97 ACUTE – Assessment of Cardioversion utilizing Transesophogeal Echocardiography (2,900

patient, multi-center, randomized trial). Sponsors: National Institute of Health & Cleveland Clinic Foundation. 7 patients enrolled.

10/96 – 10/98 AVID – Angiography versus IVUS directed coronary stent placement; effect on long term clinical

outcome. (multi-center, randomized trial). Sponsors: Scripps Research Foundation & Boston Scientific/SciMed. 23 patients enrolled.

5/97 – 9/97 MERIT – Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (multi-

center, randomized trial). Sponsor: Astra Zeneca. 9 patients enrolled.

8/97 – 11/97 PARAGON– Paragon Stent Trial (1,000 patient, multi-center, randomized trial). Sponsor:

Progressive Angioplasty Systems, Inc. 43 patients enrolled.

8/97 – 12/98 VAL-HeFT - Valsartan in Heart Failure Trial (4,310 patient, multi-center, randomized trial).

Sponsor: Ciba-Geigy Corporation. 27 patients enrolled.

12/97 – 1/98 IMPRESS – Inhibition of Metallo Protease by BMS – 1867 in a randomized exercise and

symptoms study. (532 patient multicenter randomized trial) Sponsors include Bristol-Myers Squibb. 3 patients enrolled.

12/97 – 9/99 MOST: Mode Selection Trial (2000 patient multicenter randomized trial) Sponsors include: National Institutes of Health. 8 patients enrolled.

12/97 – 2/98 WIZARD – Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders (3300 patient, multi-center, randomized trial). Sponsor: Pfizer, Inc. 38 patients enrolled.

3/98 – 4/98 EXCITE – Evaluation of Xemilofiban in Controlling Thrombotic Events (multi-center,

randomized trial). Sponsor: Searle. 16 patients enrolled.

6/98 – 6/99 TNT – Treating to New Targets (8600 patient multicenter randomized trial). Sponsors include: Parke-Davis and Pfizer, Inc. 37 patients enrolled.

7/98 – 1/05 GENECARD – Genetics of Early Onset Cardiovascular Disease (multi-center, registry trial).

Sponsor: Duke University Medical Center, Center of Human Genetics. 7 families enrolled.

9/98 – 6/99 ALIVE - Azimilide Post-Infarction survival evaluation trial (2150 patient multicenter randomized trial) Sponsors include: Proctor and Gamble Pharmaceuticals, Inc. 5 patients enrolled.

12/98 – 10/99 CADILLAC – Controlled Abciximab and Device Investigation to Lower Late Angioplasty

Complications (2,000 patient, multi-center, randomized trial). Sponsors: Advanced Cardiovascular Systems, Inc. & Lilly Research Laboratories. 11 patients enrolled.

3/99 – 6/99 PARAGON B - Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events

in a Global Organization Network (5,200 patient, multi-center, randomized trial). Sponsor: F. Hoffmann-La Roche, Ltd. 10 patients enrolled.

3/99 – 10/99 RAFT - Rythmol® SR in Atrial Fibrillation Trial (450 patient, multi-center, randomized trial).

Sponsor: Knoll Pharmaceuticals, Inc. 8 patients enrolled.

7/99 – 9/00 CURE – Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (9,000 patient, multi-center, randomized trial). Sponsors: Sanofi & Bristol Myers Squibb. 1 patient enrolled.

7/99 – 8/00 PRESTO – Prevention of Restenosis with Tranilast and its Outcome (11,500 patient, multi-center, randomized trial). Sponsor: SmithKline Beecham Pharmaceuticals. 125 patients enrolled.

8/99 – 4/01 Model 7250 - Investigational Arrhythmia Management Device (100 patient multicenter randomized trial) Sponsors include: Medtronic. 8 patients enrolled.

9/99 – 2/00 TRAFFIC – Therapeutic Angiogenesis with FGF for Intermittent Claudication (180 patient, multi-center, randomized trial). Sponsor: Chiron Corporation. 5 patients enrolled.

9/99 – 6/00 AMISTAD II - Acute Myocardial Infarction Study of Adenosine (2,100 patient, multi-center, randomized trial). Sponsor: Medco Research, Inc. 1 patient enrolled.

11/99 – 11/01 MADIT II - Multicenter Automatic Defibrillator Implantation Trial. Sponsor Guidant. 1 patient enrolled.

1/00 – 2/03 ATBAT – Anticoagulant Therapy with Bivalirudin to Assist in the performance of percutaneous coronary intervention in patients with heparin-induced Thrombocytopenia (100 patient, multi-center, open-label trial). Sponsor: The Medicines Company. 2 patients enrolled.

2/00 – 6/01 OVERTURE – Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (4840 patient multicenter randomized trial) Sponsors include: Bristol-Myers Squibb. 4 patients enrolled.

4/00 – 9/00 SAFER – Saphenous Vein Graft Angioplasty Free of Emboli Randomized Study (800 patient, multicenter, randomized trial) Sponsors include: PercuSurge Inc. 2 patients enrolled.

7/00 – 3/01 Device Far-field R-wave Discrimination- (A Randomized Prospective Study) Sponsor Medtronic. 10 patients enrolled.

8/00 – 4/01 CHESS – Comparative HDL Efficacy and Safety Study (multicenter randomized trial) Sponsors Include: Merck. 23 patients enrolled.

9/00 – 11/01 SPORTIF V: Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (3,000 patient, multi-center, randomized trial). Sponsor: Astra Zeneca. 30 patients enrolled.

9/00 – 7/01 Effect of Ad5FGF-4 on Myocardial Perfusion Defect Size and Safety in Patients with Stable Angina Study-303800 (50 patient, multi-center, randomized trial). Sponsor: Berlex Laboratories. 5 patients enrolled.

12/00 – 10/01 Response CV - A Randomized Comparison of Internal vs. External Cardioversion in Atrial Fibrillation. Sponsor: DAIG a St.Jude Medical Co. 6 patients enrolled.

12/00 – 7/01 ASSENT 3 – A Phase III Randomized, Open – Label Trial with 3 parallel groups: full dose TNK-

tPA together with heparin sodium; full dose TNK-tPA together with enoxaparin: and half dose

TNK-tPA together with abciximab and heparin sodium in patients with acute myocardial infarction.

1/01 – 2/01 REPLACE 1 – A Randomized Evaluation in PCI Linking Angiomax To Reduced Clinical Events (7,000 patient, multi-center, randomized trial) Sponsor: The Medicines Company. 9 patients enrolled.

2/01 – 5/02 P00693 – A Phase III Double-Blind Efficacy and Safety Study of SCH 59235 (10 mg) In Addition

to Atorvastatin in Subjects with Coronary Heart Disease or Multiple Cardiovascular Risk Factors

and with Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin

5/01 – 10/02 P01418 – Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to

Atorvastation in subjects with Coronary Heart Disease or Multiple Risk Factors and with Primary

Hypercholeterolemia Not Controlled by a Starting Dose (10mg) of Atorvastatin

6/01 – 3/02 NOET – TcN-Noet vs. Tc-Sestamibi (291 patient, multicenter, open label, single-crossover trial) Sponsors include CIS-US/Berlex Laboratories. 37 patients enrolled.

8/01 – 5/03 GREAT – Guided Radio Frequency Energy Ablation of Total Occlusions Using the Safe-Cross Radio Frequency Total Occlusion Crossing System (400 patient multicenter, randomized trial) Sponsors include: IntraLuminal Therapeutics, Inc. 34 patients enrolled.

9/01 – 3/02 Pre-CHILL - Evaluation of the safety and feasibility of the CVSi Cryoplasty System in patients undergoing percutaneous treatment of de novo and in-stent restenosis lesions in native coronary arteries (70 patient, multi-center, open-label trial). Sponsor: CryoVascular Systems Inc. 12 patients enrolled.

10/01 – 1/04 A Multi-center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina-304386 (450 patient multicenter randomized trial) Sponsors include: Berlex Laboratories. 6 patients enrolled.

10/01 – 9/03 Synergy – A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (8000 patients worldwide) Sponsors include: Aventis Pharmaceutical Products, Inc. 61 patients enrolled.

12/01 – 2/02 IMPACT – Kos Pharmaceuticals Inc. & DuPont Pharmaceuticals Company, “The Impact of

Medical Subspecialty on Patient Compliance to Treatment”

1/02 – 3/02 REPLACE 2 - A Randomized Evaluation in PCI Linking Angiomax To Reduced Clinical Events, Part 2 (6,000 patient, multicenter, randomized trial) Sponsors Include: The Medicines Company. 25 patients enrolled.

1/02 – 2/04 PRIDE - Protection during saphenous vein graft intervention to prevent distal embolization (800 patient multicenter randomized trial). Sponsors Include: Kensey Nash Corporation. 12 patients enrolled.

1/02 – 3/02 DELIVER - Evaluation of the RX ACHIEVE™ drug coated coronary stent system in the treatment of patients with de novo native coronary artery lesions (1,042 patient, multi-center, randomized trial). Sponsor: Advanced Cardiovascular Systems (ACS) / Guidant Corporation. 15 patients enrolled.

6/02 – 3/03 Rosuvastatin 91 – A 48 Week Open-Label, Non-Comparative, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects With Fredrickson Type IIa and Type IIb Dyslipidemia. Sponsors include: Astra Zeneca. 4 patients enrolled.

7/02 – 3/05 I-PRESERVE – Irbesartan in Heart Failure With Preserved Systolic Function (3600 multicenter, randomized trial) Sponsors Include: Bristol-Myers Squibb and Sanofi-Synthelabo. 3 patients enrolled.

8/02 – 12/02 CVSi Peripheral Balloon Catheter System Safety Registry (100 patient multicenter non-randomized registry). Sponsors Include: CryoVascular Systems, Inc. 6 patients enrolled.

10/02 – 9/03 4522IL/0099 – A 6-week Open-Label, Randomized, Multicentre, Phase IIIb, Parallel-group Study,

Which Describes the Renal Effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin

in the Treatment of Subjects with Fredrickson Type IIa, and Type IIb Dyslipidemia, Including

Heterozygous Familial Hypercholesterolemia.

12/02 – 5/03 GRIP – Guided Radio Frequency in Peripheral Total Occlusions (50 patient multicenter non-randomized registry) Sponsors include: IntraLuminal Therapeutics, Inc. 7 patients enrolled.

12/02 – 6/03 PREVAIL – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BO-653 in Prevention of Post-Angioplasty Restenosis in Stented Lesions. (600 patient, randomized trial). Sponsor: Chugai Pharmaceutical Co., Ltd. 13 patients enrolled.

1/03 – 10/04 DETECT SVT- Detection of SVT with Single Chamber vs. Dual Chamber Enhancements in Dual Chamber ICDs. Sponsor: St. Jude. 33 patients enrolled.

6/03 – 4/04 Clarity TIMI 28 – Clopidogrel as Adjunctive Reperfusion Therapy – Thrombolysis in Myocardial

Infarction –28. A randomized, Double-Blind, Placebo-controlled trial comparing clopidogrel plus

acetylsalicylic acid (ASA) versus ASA alone in subjects with acute ST elevation myocardial

infarction (STEMI) treated with Fibrinolytic therapy. 11 patients enrolled.

8/03 – 9/03 GLIDELINE XR – A multi-center, prospective trial to evaluate the safety and effectiveness of the GLIDELINE XR Polyurethane leads. Sponsors include: Guidant. 11 patients enrolled.

8/03 – 9/04 INTRINSIC RV – A two-armed, randomized trial to compare the effects of innovative dual-chamber pacing with AVSH to standard VVI among ICD patients. (1250 patient, randomized trial). Sponsors include: Guidant. 36 patients enrolled.

8/03 - 5/05 TALON – A Prospective, Multi-Center, Observational Outcomes Database Registry. Sponsors

include: FoxHollow. 196 patients enrolled.

8/03 – 6/05 ARISE – A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AGI-1067 in Reducing Cardiovascular Events in Patients with CAD. (4000 patient, randomized trial). Sponsor: AtheroGenics, Inc. 11 patients enrolled.

9/03 – 8/04 4522US/0007 – Starship – A 6wk, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the treatment of Hypercholesterolemia in Hispanic Subjects. 21 patients enrolled

10/03 – 6/04 DECREASE HF- Device Evaluation of CONTAK RENEWAL 2/4/4HE and EASYTRAK 2: Assessment of Safety and Effectiveness in Heart Failure. Sponsor: Guidant Corp. 3 patients enrolled.

12/03 – 6/05 COMBAT – A Non-Randomized Registry Study Using the FOXHOLLOW Coronary Debulking Catheter System in the Treatment of Bifurcation Lesions in Native Coronary Arteries (250 patient multicenter trial) Sponsors include: FOXHOLLOW. 3 patients enrolled.

12/03 – 7/05 AMADEUS – A Non-inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous Idraparinux with Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patient with Atrial Fibrillation (600 patient, multicenter, randomized trial) Sponsors include: Organon. 110 patients enrolled.

12/03 – 7/05 ACUITY – A Randomized Comparison of Angiomax vs. Lovenox in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-segment Elevation (13,800 patient, randomized, multicenter trial) Sponsors include: The Medicines Company. 35 patients enrolled.

12/03 – 6/06 CVT 5131 – A Randomized, Double-Blind, Study of Intravenous CVT-3146 vs. Adenosine in Patients Undergoing Stress Myocardial Perfusion Imaging (855 patient multicenter trial) Sponsors include: CV Therapeutics, Inc. 24 patients enrolled.

8/04 – 2/05 REFLEX-A Randomized comparison of ENDOTAK RELIANCE G leads to all US market approved Guidant, Medtronic, St. Jude active-fixation dual coil endocardial defibrillation. 12 patients enrolled.

11/04 – 7/05 TRENDS- A post-marking study to evaluate the stroke risk predictive value stored in IPG, ICD, and CRT devices. Sponsor: Medtronic. 17 patients enrolled.

11/04 – 2/05 DISPERSE2 – TIMI 33 – A Double-blind, Double-dummy, Parallel Group Randomized Dose

Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid Compared with

Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes. 5 patients enrolled.

1/05 – 4/05 SITELINE- Clinical Investigation of SITELINE APL Silicone Pace/Sense Lead. Sponsor: Guidant Corp. 6 patients enrolled.

4/05 – 1/07 TRITON-TIMI 38 – A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo percutaneous Coronary Intervention (13,000 patient, randomized, multicenter trial) Sponsors include: Eli Lilly and Company. 31 patients enrolled.

4/05 – 10/05 ICE-PAF- Clinical Study to Evaluate the Safety and Efficacy of the CRYOCOR Cardiac Cryoablation System for the Treatment of Atrial Fibrillation. Sponsor: CryoCor Inc. 5 patients enrolled.

4/05 – 5/07 RIATA- Riata I integrated bipolar and Riata dedicated bipolar defibrillation leads in patients who have a standard indication for a CRT device. Sponsor: St. Jude. 9 patients enrolled.

5/05 – 5/05 EASYTRAK 4 STEERABLE Clinical Investigation of EASYTRAK 4 STEERABLE LV lead. Sponsor: Guidant Corp. 3 patients enrolled.

5/05 – 12/07 PEGASUS- A Randomized, Prospective, Single blind, Three Arm Study to Assess Atrial Support Pacing in a CRT Defibrillator Programmed to DDD-70, DDDR-40 compared to DDD-40. Sponsor: Guidant Corp. 24 patients enrolled.

7/05 – 7/06 ACROSS-Cypher – Approaches to Chronic Occlusions with Sirolimus Stents-Cypher (250 patient, multicenter trial) Sponsors include: David Kandzari, M.D. and Duke Clinical Research Institute. 8 patients enrolled.

7/05 – 10/05 Early ACS – Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary

Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-

loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary

Syndrome. 4 patients enrolled.

8/05 – 4/06 COSTAR II – Cobalt Chromium Stent with Antiproliferative for Restenosis II Trial (1700 patient, multicenter, randomized trial) Sponsors include: Conor Medsystems. 27 patients enrolled.

8/05 – 11/06 CAPTURE – Carotid RX ACCULINK/ACCUNET Post-Approval Trial to Uncover Unanticipated and Rare Events (500 patient, multi-center, observational, post-approval trial) Sponsors include: Guidant Corporation. 32 patients enrolled.

9/05 – 4/06 SPIRIT III – A Randomized, Multi-Center, Clinical Trial Evaluating the Safety and Efficacy of the XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects with de novo Native Coronary Artery Lesions. Sponsors include: Guidant Corporation. 2 patients enrolled.

10/05 – 1/06 ULTRA- Automatic Capture On versus patients randomized to automatic Capture OFF.(950 Patient, Prospective, Multi-center study) Sponsors include: Guidant. 5 patients enrolled

11/05 – 1/06 AFFECTS –Examine current physician practice in atrial fibrillation (AF) treatment (5,000 Patient,

Open label, observational study) Sponsors include: Reliant Pharmaceuticals. 4 patients enrolled.

11/05 – 3/06 OSIRIS – A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation,

Multi-center Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel™) Following Acute Myocardial Infarction. (48 patient, randomized trial). Sponsors include Osiris Therapeutics. 5 patients enrolled.

1/06 – 10/06 PROVE - Programming ventricular tachycardia therapy for patients that need AICD. Sponsor: St Jude. 4 patients enrolled.

1/06 – 3/06 RED-TAIL – Registry of SFA Bilateral Disease Treated with the SilverHawk System. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollow. 5 patients enrolled.

1/06 – 5/06 MERLIN – Multiple Lesions from a Unilateral Extremity Treated with SilverHawk in a Single Procedure. (Multi-center, prospective, outcomes database registry) Sponsors include: FoxHollow. 32 patients enrolled.

2/06 – 1/07 EXACT – Emboshield and Xact Post Approval Carotid Stent Trial (Multi-center, Observational, Single Arm, Post-Approval Study); Sponsors include: Abbott Vascular Devices. 18 patients enrolled.

3/06 – 12/07 RELY – Randomized, Evaluation of Long term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexialte with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: Prospective, Multi-center, Parallel-group, Non-inferiority Trial. (15,000 patient, randomized trial). Sponsors include Boehringer Ingelheim. 198 patients enrolled.

3/06 – 7/10 IMPROVE- IT – IMProve Reduction of Outcomes: Vytorin Efficacy International Trial (10,000 patient, multicenter, double-blind, randomized trial) Sponsors include: Schering-Plough Research Institute. Location – Heart Hospital and San Marcos. 59 patients enrolled.

5/06 – 6/07 LEAP – A Two-part, Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Effects of Simvastatin, Losartan, and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Arterial Disease. Sponsor: FoxHollow. 8 patients enrolled.

6/06 – 1/07 SWIFT – Femoropopliteal Disease Treated With the SilverHawk Plaque Excision System: A Non-Randomized Registry with Duplex Ultrasound Follow Up At Twelve Months. Sponsor: FoxHollow. 8 patients enrolled.

7/06 – 12/07 PATRICIA – A Multi-center, Randomized, Open-Label Trail of Intra-Renal Fenoldopam Mesylate Vs. Intravenous Sodium Bicarbonate and Oral N-acetylcysteine in Patients at High Risk for Contrast Induced Nephropathy Undergoing Peripheral Vascular Intervention. Sponsor: FlowMedica. 2 patients enrolled.

9/06 – 6/07 FOCUS – Follow up Of Clinical Outcomes: The Long-term AGI-1067 plus Usual Care Study (Patients that wish to continue from the ARISE Study) Sponsors include: AtheroGenics, Inc. 9 patients enrolled.

9/06 – 1/13 ACT I – Carotid Angioplasty and Stenting versus Endarterectomy in Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease (1540 patient, multicenter, randomized trial) Sponsors include: Abbott Vascular. Location – Heart Hospital. 79 patients enrolled.

12/06 – 7/08 PLATO – A Study of PLATelet inhibition and Patient Outcome (18,000 patient, multicenter,

randomized, double-blind trial) Sponsors include: AstraZeneca. Location – Heart Hospital.

60 patients enrolled.

12/06 – 3/09 RESPECT - Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (400 patient, post-approval trial) Sponsors Include: Medtronic. Location – Heart Hospital. 7 patients enrolled.

2/07 – 3/12 CHOICE – Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through Collection of Clinical Evidence (Open ended enrollment, non-randomized, multicenter trial) Sponsors include: Abbott Vascular. Location – Heart Hospital. 297 patients enrolled.

3/07 – 12/07 BROADWING- “Biological Waste MateRial and Outcomes Analysis of Lower Extremity Peripheral Disease Treated With the SIlverHawk™ Plaque ExcisioN System: A Tissue and Data ReGistry” Sponsor: FoxHollow. 1 patient enrolled.

3/07 – 5/09 CHAMPION Platform – Cangrelor versus standard therapy to achieve optimal management of platelet inhibition (4400 patient, multicenter, randomized trial) Sponsors include: The Medicines Company. Location – Heart Hospital. 39 patients enrolled.

6/07 – 6/08 PROTECT – Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (320 patient, multicenter, non-randomized trial) Sponsors include: Abbott Vascular. Location – Heart Hospital. 17 patients enrolled.

8/07 – 12/07 NIGHTHAWK – Evaluation of the NightHawk peripheral excision system for patients with infrainguinal lesions. (20 patient, non-randomized, multicenter trial) Sponsors include: FoxHollow Technologies, Inc. 15 patients enrolled.

10/07 – 10/07 PLASMA 2 – Phospholipase Levels And Serological Markers of Atherosclerosis 2 (120 patient, randomized, double-blind, placebo-controlled trial) Sponsors include: Anthera Pharmaceuticals, Inc. Location – Medical Park Tower. 6 patients enrolled.

10/7 – 7/09 OM8 – To Assess the Efficacy and Safety of Omacor for the Prevention of Recurrent, Symptomatic Atrial Fibrillation (660 patient, randomized, double-blind, placebo-controlled trial) Sponsors include: Reliant Pharmaceuticals, Inc. Location – Medical Park Tower. 14 patients enrolled

11/07 – 11/09 TIMI 50 – Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (20,000 patient, randomized, double blind, placebo-controlled, multi-national trial) Sponsors include: Schering-Plough Research Institute. Location – Heart Hospital, MPT, San Marcos and Killeen. 110 patients enrolled.

1/08 – 9/08 PASCAL – Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Capabilities (140 patient, randomized, double-blind, placebo-controlled trial) Sponsors include: ARYx Therapeutics. Location – Medical Park Tower. 2 patients enrolled.

1/08 – 4/09 EMINENCE – Evaluation of M118 in Percutaneous Coronary Intervention (600 patient, multicenter, randomized, open-label trial) Sponsors include: Momenta Pharmaceuticals. Location – Heart Hospital. 45 patients enrolled.

1/08 – 4/09 PACE MI – Pacemaker and Beta-Blocker Therapy after Myocardial Infarction Trial (562 patient, multicenter, randomized trial) Sponsors include: Dr. Jeff Goldberger at Northwestern University and National Institutes of Health. Location – Heart Hospital.

2/08 – 5/08 POINT 3 – A Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive

Technology Using PB127 Ultrasound Contrast Agent in Patients with Suspected Obstructive

Coronary Artery Disease II (850 patient, open label, multicenter trial) Sponsors include: POINT

Biomedical Corporation. Location – Medical Park Tower. 4 patients enrolled.

3/08 – 4/09 AFI-30 – Tailored Treatment of Permanent Atrial Fibrillation (210 patient, multicenter, randomized trial) Sponsors include: Ablation Frontiers. Location – Heart Hospital. 14 patients enrolled.

8/08 – On Hold RBM – Luminex xMAP (multianalyte profile) to diagnose ACS patients using blood biomarker

profiles (200 patient, single-center study) Sponsors include: Rules Based Medicine. Location –

Heart Hospital. 178 patients enrolled.

9/08 – 1/11 ENDEAVOR – Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novo Lesions in Small Diameter Native Coronary Arteries (300 patient, prospective, multicenter, open-label trial) Sponsors include: Medtronic Location – Heart Hospital.

3 patients enrolled.

9/08 – 12/08 XIENCE V – Everolimus Eluting Coronary Stent System USA Post-Approval Study (5000 patient, open-label, multicenter, single-arm registry) Sponsors include: Abbott Cardiovascular Systems, Inc. Location – Heart Hospital. 126 patients enrolled.

10/08 – 6/10 Dal-Outcomes – RO4607381 on cardiovascular risk in stable CHD patients, with a documented

recent Acute Coronary Syndrome (15,600 patient, double-blind, randomized, placebo-controlled

study) Sponsors include: Hoffman La-Roche, Inc. Location – Heart Hospital, San Marcos, and

Round Rock. 68 patients enrolled

11/08 – 1/10 SMART AV – Smart Delay compared to other AV delay methods used in CRT. (950 patient,

randomized, multi-center, double-blind, 3 arm trial) Sponsors include: Boston Scientific. Location – Heart Hospital and Round Rock. 47 patients enrolled.

1/09 – 3/09 RELY-Able – Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial

Fibrillation Who Completed the RE-LY Trial. Sponsors include: Boehringer Ingelheim.

Location – Heart Hospital, San Marcos, MPT and Killeen. 89 patients enrolled

3/09 – 4/10 GRAVITAS – VerifyNow Assay for pts that (1532 patient, prospective, randomized, multicenter

study) Sponsors include Accumetrics and Synteract. Location – Heart Hospital. 27 patients enrolled.

3/09 – 12/10 OSIRIS – A Phase II, multi-center, randomized, double-blind, placebo-controlled study to

evaluate the safety and efficacy of PROCHYMAL® intravenous infusion following acute myocardial infarction (220 patient, randomized trial). Sponsors include: Osiris Therapeutics. Location – Heart Hospital. 22 patients enrolled.

4/09 – 9/09 PLATINUM – Everolimus-Eluting Coronary Stent for the treatment of coronary lesions (1532

patient, prospective, randomized, multicenter study) Sponsors include Boston Scientific. Location – Heart Hospital. 7 patients enrolled.

4/09 – 9/09 STABILITY – Darapladib vs. placebo in chronic CHD patients with first MACE event (15,500

patient, randomized, double-blind, parallel group, multi-center study) Sponsors include; GlaxoSmithKline. Location – Killeen office. 13 patients enrolled.

8/09 – 9/10 PROVIDE – Programming Implantable Cardioverter Defibrillators to Prolong Time to First Shock (1600 patient, randomized, multicenter study) Sponsors include: St. Jude. Location – Round Rock office. 44 patients enrolled.

9/09 – 10/10 Definitive Ca++ – SilverHawk LS-C with the SpiderFX in lower extremity PAD undergoing plaque excision. (102 patient, prospective, multi-center, non-randomized, single-arm study) Sponsors include: EV3. Location – Heart Hospital. 13 patients enrolled.

9/09 – 5/11 SUPERB – SUPERA Nitinol Stent System in treating subjects with obstructive SFA disease. (258

Patient, Prospective, Multi-center, Non-randomized, Single-arm Trial). Sponsors include: Idev

Technologies Inc. Location – Heart Hospital. 17 patients enrolled.

11/09 – 5/14 ACUITY – Longitudinal Surveillance Registry of the ACUITY Spiral Lead. (1700 Patient,

Prospective, Non-Randomized Registry) Sponsors include: Boston Scientific. Location – Heart

Hospital. 6 patients enrolled.

12/09 – 2/10 Spirit PRIME – XIENCE PRIME and XIENCE PRIME LL for treatment of coronary lesions.

(500 Patient, Prospective, two-arm, open-label, multi-center Registry) Sponsors include: Abbott

Cardiovascular Systems Inc. Location – Heart Hospital. 4 patients enrolled.

1/10 – 2/10 RAAFT - First Line Radiofrequency Ablation versus Antiarrhythmic Drugs for Atrial Fibrillation

Treatment: (400 Patient, Multi-center Randomized Trial) Sponsors include: Andrea Natale, M.D. Location – Heart Hospital. 3 patients enrolled.

1/10 – 3/10 STROLL – S.M.A.R.T.™ Nitinol Self-Expandable Stent System in treating patients with SFA

disease. (250 Patient, Multi-center, non-randomized, single-arm, prospective trial). Sponsors

include: Cordis. Location – Heart Hospital. 0 patients enrolled.

1/10 – 4/11 SOLSTICE – GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with STEMI (500 Patient, Randomized, Double-blind, Placebo-controlled study) Sponsors include: GlaxoSmithKline. Location – Heart Hospital and Round Rock. 9 patients enrolled.

1/10 – 5/12 MADIT–RIT – Multicenter Automatic Defibrillator Implantation Trial: Reduce Inappropriate

Therapy. (1500 Patient, Prospective, Randomized, 3-arm trial) Sponsors include: Boston

Scientific. Location – Heart Hospital. 35 patients enrolled.

2/10 – 7/11 DAPT – Dual Anti-platelet therapy in subjects undergoing PCI with either DES or BMS placement for the treatment of coronary artery lesions. 20,645 Patient, Multi-center, Randomized, Double-blind Trial) Sponsors include: HCRI . Location – Heart Hospital. 62 patients enrolled.

5/10 – 10/11 SOLID – TIMI 52 - The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 (11,500 Patient, Multi-center, Randomized, Double-blind Trial) Sponsors include: GlaxoSmithKline. Location – Heart Hospital, Medical Park Tower, Round Rock, San Marcos and Killeen. 35 patients enrolled.

9/10 – 8/13 MultiSENSE – Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients (450 Patient, Multi-Center, Non-randomized, Prospective Trial) Sponsors include: Boston Scientific CRM. Location – Heart Hospital. 19 patients enrolled.

1/11 – 4/13 PEGASUS TIMI 54 – Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk

Patients with Prior Acute Coronary Syndrome. (13,500 patient, Randomized, Double-blind,

Placebo-controlled trial) Sponsors include AstraZeneca Location – Heart Hospital and Round

Rock. 30 patients enrolled

2/11 – 3/11 CONNECT - Chronic Total Occlusion Crossing with the WildCat Catheter (77 Patient,

Prospective, Multi-center, Non-randomized trial). Sponsors include: Avinger. Location – Heart

Hospital. 4 patients enrolled

2/11 – 8/12 CHAMPION Phoenix - Cangrelor versus standard therapy to achieve optimal management of

platelet inhibition. (10,900 patient, Randomized, double blind, placebo-controlled trial) Sponsors

include: The Medicines Company. Location – Heart Hospital office and Round Rock. 126

patients enrolled

2/11 – 11/12 BioMet - MarrowStim™ PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects

with Severe PAD (152 patient, Double-Blind, Placebo-Controlled, Multi-Center Trial) Sponsors

include: Biomet Biologics. Location – Heart Hospital. 0 patients enrolled.

2/11 – 9/11 SAVOR TIMI 53 - Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with

Diabetes Mellitus. (12,000 Patient, Multi-Center, Double-Blind, Placebo-Controlled Trial) Sponsors include: AstraZeneca & Bristol Myers Squibb. Location – Heart Hospital. 13 patients

enrolled

6/11 – 8/13 Levant 2 – Moxy™ Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries. (500 Patient, Prospective, Multi-center, Single-Blind, Randomized, Trial) Sponsors include: Lutonix, Inc. Location – Heart Hospital. 33 patients enrolled.

7/11 – 7/12 RESPECT – VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy after Percutaneous Endovascular Procedures (420 Patient, Multi-center, Prospective, Randomized Trial) Sponsors Include: Cardiva. Location – Heart Hospital. 74 patients enrolled.

7/11 – 11/12 Tryton – Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side-branch Balloon Angioplasty in Conjunction with a Drug-eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within Native Coronary Circulation. (704 Patient, Multi-center, Single-Blind, Randomized Trial) Sponsors include: Tryton Medical, Inc. Location – Heart Hospital. 11 patients enrolled.

2/12 – 4/12 REVEAL – Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (30,000 Patient, Multi-center, Worldwide, Randomized Trial) Sponsors include: Oxford University, The TIMI Group and Merck. Location – Heart Hospital and San Marcos. 47 patients enrolled.

3/12 – 11/12 BI-GI – Efficacy of pantoprazole 40 mg q.a.m. or taking Pradaxa® alone with food (within 30

minutes after a meal)) on gastrointestinal symptoms (70 patient, prospective, open label study)

Sponsors Include: Boehringer Ingelheim. Location – Killeen. 1 patient enrolled.

3/12 – 8/13 Symplicity HTN-3 – Renal Denervation in Patients with Uncontrolled Hypertension (1060 Patient, Multi-center, Blinded, Randomized Trial) Sponsors include: Medtronic Ardian. Location – Heart Hospital. 13 patients enrolled.

4/12 – 8/14 Laptop – Left Atrial Pressure Monitoring to Optimize Heart Failure (730 Patient, Multicenter, Randomized Trial). Sponsors include: St. Jude Medical. Location – Heart Hospital and San Marcos. 14 patients enrolled

5/12 – 8/13 RAID – Ranolazine ICD Trial Late Sodium Current Blockade in High-Risk ICD Patients. (1440 Patient, Randomized, Double-blind, Placebo-controlled trial) Sponsors include: NIH. Location – Heart Hospital. 3 patients enrolled.

5/12 – 9/13 EXCEL – Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness

of Left Main Revascularization (3500 Patient, Multi-center, Prospective, Randomized Trial)

Sponsors include: Abbott Vascular. Location – Heart Hospital. 3 patients enrolled.

6/12 – 6/12 FLEXION – Clinical Evaluation of TherapyTM Cool FlexTM Irrigated Ablation Catheter System for

the Treatment of Typical Atrial Flutter (200 patient, multi-center, non-randomized clinical study)

Sponsors Include: St. Jude. Location – Heart Hospital. 2 patients enrolled.

7/12 – 11/12 CONNECT II – Avinger Ocelot System to cross chronic total occlusions in the superficial femoral and popliteal arteries. (114 patient Prospective, Multi-center, Non-randomized Trial) Sponsors include: Avinger. Location – Heart Hospital. 14 patients enrolled

9/12 – 6/13 Accent MRI – Accent MRI System in a patient population indicated for implant of a pacemaker

within and outside of the MRI environment. (800 patient, Prospective, Multi-center Trial)

Sponsors include: St Jude. Location – Heart Hospital. 58 *patients enrolled.*